Company / Current Liabilities
Moleculin Biotech, Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$6.9M
FY2025
5-year range
$3.6M / $6.9M
FY2021-FY2025
Trend
+27.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has fluctuated over the past 10 years, ranging from $1M in FY2016 to $7M in FY2025.
Based on SEC 10-K filings.
$7M in FY2025 with a 5-year CAGR of +18.6%.
Remained stable around $7M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +12.5%
- 5-Year CAGR
- +18.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +18.6%, indicating consistent growth.
- In FY2025, current liabilities increased 27.9% year-over-year.
- Lowest current liabilities in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -3.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.9M | +27.9% |
| FY2024 | $5.4M | -21.4% |
| FY2023 | $6.8M | +41.4% |
| FY2022 | $4.8M | +33.0% |
| FY2021 | $3.6M | +24.0% |
| FY2020 | $2.9M | -18.2% |
| FY2019 | $3.6M | -7.9% |
| FY2018 | $3.9M | +75.1% |
| FY2017 | $2.2M | +64.7% |
| FY2016 | $1.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026